Pfizer Boost FY24 Adj. EPS Outlook - Update

RTTNews | 21 일 전
Pfizer Boost FY24 Adj. EPS Outlook - Update

(RTTNews) - While reporting financial results for the first quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings guidance for the full-year 2024, while maintaining annual revenue outlook.

For fiscal 2024, the company now projects adjusted earnings in a range of $2.15 to $2.35 per share, up from the prior guidance range of $2.05 and $2.25 per share.

However, the company continues to project revenues between $58.5 billion and $61.5 billion, with revenues of about $5 billion for Comirnaty, about $3 billion for Paxlovid and about $3.1 billion from legacy Seagen.

On average, 23 analysts polled by Thomson Reuters expect the company to report earnings of $2.21 per share on revenues of $60.02 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Amazon, Microsoft, Pfizer To Invest Billions In French Projects

Amazon, Microsoft, Pfizer To Invest Billions In French Projects

Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.
RTTNews | 9 일 전
Pfizer Closes $43 Bln All-cash Acquisition Of Seagen

Pfizer Closes $43 Bln All-cash Acquisition Of Seagen

Pfizer Inc. (PFE) announced Thursday the successful completion of its acquisition of biotechnology company Seagen Inc. (SGEN). Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.
RTTNews | 160 일 전
Pfizer Reaffirms FY23 Outlook - Update

Pfizer Reaffirms FY23 Outlook - Update

While reporting financial results for the third quarter, drug major Pfizer Inc. (PFE) reaffirmed its adjusted earnings and revenue guidance for the full-year 2023.
RTTNews | 204 일 전
Pfizer's Hospira Recalls Sodium Bicarbonate, Lidocaine HCl Injections

Pfizer's Hospira Recalls Sodium Bicarbonate, Lidocaine HCl Injections

Hospira, Inc., owned by drug major Pfizer Inc., is recalling certain Sodium Bicarbonate and Lidocaine HCl Injections citing the potential for presence of glass particulate matter, the U.S. Food and Drug Administration said. The recall involves 4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10mL vial; 1% Lidocaine HCl Injection, USP, 50 mg/5mL vial; and 2% Lidocaine HCl Injection, USP, 100 mg/5mL.
RTTNews | 232 일 전
CDC Recommends Updated Pfizer, Moderna COVID-19 Vaccine

CDC Recommends Updated Pfizer, Moderna COVID-19 Vaccine

The Centers for Disease Control and Prevention or CDC has recommended everyone 6 months and older to get an updated COVID-19 vaccine ahead of the virus season this fall and winter. The agency expects the updated COVID-19 vaccines from Pfizer-BioNTech and Moderna, which was approved by the U.S. Food and Drug Administration earlier this week, to be available later this week.
RTTNews | 252 일 전
FDA Approves Pfizer's Abrysvo For Pregnant Individuals To Prevent RSV In Infants

FDA Approves Pfizer's Abrysvo For Pregnant Individuals To Prevent RSV In Infants

The U.S. Food and Drug Administration announced the approval of Pfizer Inc.'s Abrysvo (Respiratory Syncytial Virus Vaccine) for use in pregnant individuals to prevent respiratory syncytial virus or RSV in infants. It is the first vaccine approval for use in pregnant individuals to prevent lower respiratory tract disease or LRTD and severe LRTD caused by RSV in infants from birth through 6 months..
RTTNews | 274 일 전